We are excited to announce the closing of a €1.1 million funding round to drive our innovative blood analysis for the early detection of five types of cancer (colorectal, lung, breast, prostate, and pancreatic).
This funding round was led by a prominent US Family Office and supported by key investors such as Decelera Ventures, FCR, Histemi Inversiones, and the Dr. Rosell Oncology Institute (IOR).
Building on the success of the seed round in 2022, this new funding will be crucial for advancing the preclinical validation of our liquid biopsy technology, combining next-generation sequencing (NGS) of RNA biomarkers and artificial intelligence. The funds will be allocated to validate our non-invasive liquid biopsy, sample processing protocols, pipelines, and libraries for the bioinformatic processing we have defined in the research process.
João Curado, CEO and co-founder, has expressed gratitude for the support received, emphasizing that this financial backing will enable the expansion of preclinical studies and pave the way for clinical trials. Private funding complements the public grants and subsidies awarded to Flomics, consolidating our commitment to advancing cancer early detection and improving patient outcomes.
The trust placed in us by our investors is a testament to the potential and promise of our work and advancements. We remain committed to leading the way in the fight against cancer, using advanced RNA-based approaches.
We extend our gratitude to our investors, partners, and team for their continuous support and dedication. Together, we are driving innovation and moving towards a future where cancer is a manageable and ultimately curable disease.
